Showing results (121-130 of 279) with videos related to
Sort By:
Pageof 28
Breast Cancer Research and Treatment|November 26, 2010
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancerGuy Jerusalem, Angelica Fasolo, Veronique Dieras, et al.British Journal of Clinical Pharmacology|July 27, 2020
Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 allelesLinda Thorén, Jonatan D Lindh, Gerd Ackehed, et al.Ebiomedicine|September 19, 2019
Generation of in situ sequencing based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast cancerJessica Svedlund, Carina Strell, Xiaoyan Qian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2012
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progressionLinda Sofie Lindström, Eva Karlsson, Ulla M Wilking, et al.Breast Cancer Research and Treatment|February 14, 2018
Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trialKim C Aalders, Nathan Touati, Konstantinos Tryfonidis, et al.Journal of the National Cancer Institute|November 3, 2005
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trialBo Nordenskjöld, Johan Rosell, Lars-Erik Rutqvist, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancerMervi Laakso, Minna Tanner, Jonas Nilsson, et al.Molecular Oncology|March 3, 2020
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive diseaseIoannis Zerdes, Emmanouil G Sifakis, Alexios Matikas, et al.Breast Cancer Research and Treatment|September 19, 2018
Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registryClaudette Falato, Sara K Taylor, Robert Szulkin, et al.European Journal of Cancer (Oxford, England : 1990)|April 3, 2007
A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancerKenneth Villman, John F Ohd, Elisabet Lidbrink, et al.Pageof 28